Lonza agrees to acquire five US CDMO sites from Merck KGaA
Company / institutional announcement · Lonza
Source published: · Event / reporting date: 2026-11-03
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Lonza signed an agreement to acquire five US CDMO sites from Merck KGaA, adding bioconjugation, payload-linker, viral vector, and advanced delivery capabilities. Closing is expected in mid-2027, subject to customary conditions. Until then, the businesses will continue operating independently.
Why it may matter
The deal may reshape US outsourcing options for complex modalities; customers should confirm future capabilities and supply continuity.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections